Glycoprotein N-linked glycans play a critical role in arenavirus pathogenicity.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
03 2021
Historique:
received: 09 10 2020
accepted: 03 02 2021
revised: 11 03 2021
pubmed: 2 3 2021
medline: 23 7 2021
entrez: 1 3 2021
Statut: epublish

Résumé

Several arenaviruses cause hemorrhagic fevers in humans with high case fatality rates. A vaccine named Candid#1 is available only against Junin virus (JUNV) in Argentina. Specific N-linked glycans on the arenavirus surface glycoprotein (GP) mask important epitopes and help the virus evade antibody responses. However the role of GPC glycans in arenavirus pathogenicity is largely unclear. In a lethal animal model of hemorrhagic fever-causing Machupo virus (MACV) infection, we found that a chimeric MACV with the ectodomain of GPC from Candid#1 vaccine was partially attenuated. Interestingly, mutations resulting in acquisition of N-linked glycans at GPC N83 and N166 frequently occurred in late stages of the infection. These glycosylation sites are conserved in the GPC of wild-type MACV, indicating that this is a phenotypic reversion for the chimeric MACV to gain those glycans crucial for infection in vivo. Further studies indicated that the GPC mutant viruses with additional glycans became more resistant to neutralizing antibodies and more virulent in animals. On the other hand, disruption of these glycosylation sites on wild-type MACV GPC rendered the virus substantially attenuated in vivo and also more susceptible to antibody neutralization, while loss of these glycans did not affect virus growth in cultured cells. We also found that MACV lacking specific GPC glycans elicited higher levels of neutralizing antibodies against wild-type MACV. Our findings revealed the critical role of specific glycans on GPC in arenavirus pathogenicity and have important implications for rational design of vaccines against this group of hemorrhagic fever-causing viruses.

Identifiants

pubmed: 33647064
doi: 10.1371/journal.ppat.1009356
pii: PPATHOGENS-D-20-02227
pmc: PMC7951981
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Viral Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009356

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM007753
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist. Author Milagros Miller was unable to confirm their authorship contributions. On their behalf, the corresponding author has reported their contributions to the best of their knowledge.

Références

J Virol. 2011 Feb;85(4):1473-83
pubmed: 21123388
Viruses. 2012 Jan;4(1):83-101
pubmed: 22355453
Cell Host Microbe. 2015 Dec 9;18(6):705-13
pubmed: 26651946
J Virol. 2014 Feb;88(4):1914-23
pubmed: 24284323
J Virol. 2008 Jan;82(2):938-48
pubmed: 18003730
Virology. 2011 Jan 20;409(2):223-33
pubmed: 21056893
Virology. 1989 Aug;171(2):417-26
pubmed: 2474891
J Virol. 2014 Sep;88(18):10995-9
pubmed: 25031335
J Clin Virol. 2015 Mar;64:120-7
pubmed: 25549822
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2664-9
pubmed: 18268337
PLoS Pathog. 2015 Nov 20;11(11):e1005276
pubmed: 26587982
Am J Trop Med Hyg. 1965 Sep;14(5):808-13
pubmed: 5829142
Am J Epidemiol. 1974 Jun;99(6):425-33
pubmed: 4601699
Nat Struct Mol Biol. 2010 Apr;17(4):438-44
pubmed: 20208545
Immunol Today. 2000 Jan;21(1):35-41
pubmed: 10637557
Bull Pan Am Health Organ. 1991;25(2):118-26
pubmed: 1654168
Science. 1984 Dec 14;226(4680):1328-30
pubmed: 6505693
J Virol. 2015 Nov 18;90(3):1290-7
pubmed: 26581982
Viruses. 2012 Oct 17;4(10):2162-81
pubmed: 23202458
Virol J. 2018 Jun 7;15(1):99
pubmed: 29879985
J Mol Biol. 2013 Dec 13;425(24):4893-903
pubmed: 24075870
J Virol. 2017 Nov 14;91(23):
pubmed: 28931684
J Virol. 2011 Nov;85(21):11058-68
pubmed: 21880772
Front Cell Infect Microbiol. 2017 Feb 06;7:20
pubmed: 28220142
Curr Opin Virol. 2014 Apr;5:82-90
pubmed: 24636947
Nature. 2007 Mar 1;446(7131):92-6
pubmed: 17287727
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12701-5
pubmed: 11606739
J Virol. 2015 Jun;89(11):5949-56
pubmed: 25810546
Nat Commun. 2018 May 14;9(1):1884
pubmed: 29760382
Virology. 1990 Jul;177(1):175-83
pubmed: 2141203
J Mol Biol. 2018 Jun 22;430(13):1839-1852
pubmed: 29705070
J Exp Med. 2006 Aug 7;203(8):2033-42
pubmed: 16880253
Am J Trop Med Hyg. 1966 Jan;15(1):103-6
pubmed: 5901620
Virol J. 2006 May 31;3:41
pubmed: 16737539
Virol J. 2013 Jul 02;10:221
pubmed: 23816343
PLoS Negl Trop Dis. 2016 Aug 31;10(8):e0004969
pubmed: 27580122
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
J Virol. 2011 Dec;85(24):13457-62
pubmed: 21976641
Hum Vaccin. 2011 Jun;7(6):694-700
pubmed: 21451263
J Virol. 2020 Mar 31;94(8):
pubmed: 31996435
Sci Rep. 2017 Jul 5;7(1):4679
pubmed: 28680057
Science. 2017 Jun 2;356(6341):923-928
pubmed: 28572385
Nat Rev Microbiol. 2008 Feb;6(2):143-55
pubmed: 18197170
PLoS Pathog. 2008 Apr 18;4(4):e1000047
pubmed: 18421377
J Virol. 2011 Oct;85(19):10404-8
pubmed: 21795336
Vaccine. 2001 May 14;19(25-26):3331-46
pubmed: 11348697
Virology. 2006 Sep 1;352(2):345-56
pubmed: 16777170
J Virol. 2015 Oct 28;90(2):705-14
pubmed: 26512085
PLoS One. 2013;8(1):e53273
pubmed: 23308183
Virology. 2007 Mar 1;359(1):72-81
pubmed: 17045626
Elife. 2020 May 26;9:
pubmed: 32452770
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7320-7325
pubmed: 29941589
Cell. 2019 May 16;177(5):1086-1088
pubmed: 31100263
J Virol. 2020 Feb 14;94(5):
pubmed: 31801871
mBio. 2014 Oct 28;5(6):e02063
pubmed: 25352624
J Virol. 2017 Dec 14;92(1):
pubmed: 29070682
J Virol. 2020 Apr 16;94(9):
pubmed: 32051278

Auteurs

Takaaki Koma (T)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

Cheng Huang (C)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

Adrian Coscia (A)

Department of Microbiology, Harvard Medical School, Boston, Massachusetts, United States of America.

Steven Hallam (S)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

John T Manning (JT)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

Junki Maruyama (J)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

Aida G Walker (AG)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

Milagros Miller (M)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

Jeanon N Smith (JN)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

Michael Patterson (M)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

Jonathan Abraham (J)

Department of Microbiology, Harvard Medical School, Boston, Massachusetts, United States of America.

Slobodan Paessler (S)

Department of Pathology, University of Texas Medical Branch at Galveston, Texas, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH